;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • 23andMe, Pfizer deal

    23andMe Inc., Mountain View, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Autoimmune 23andMe partnered with Pfizer to explore the genetic factors associated with the onset, progression, severity and response …

    Published on 8/18/2014
  • Actelion, PatientsLikeMe deal

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland PatientsLikeMe Inc., Cambridge, Mass. Business: Cancer Actelion has provided undisclosed funding to PatientsLikeMe to create a patient-reported outcomes tool for mycosis …

    Published on 8/18/2014
  • Anacor, Novartis deal

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Infectious Anacor granted Novartis Sandoz Inc. generics unit exclusive rights in the U.S. to …

    Published on 8/18/2014
  • Arena, Teva deal

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Endocrine/Metabolic Arena granted Tevas Abic Marketing Ltd. subsidiary exclusive…

    Published on 8/18/2014
  • Basilea, Quintiles deal

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Quintiles Transnational Holdings Inc. (NYSE:Q), Research Triangle Park, N.C. Business: Infectious Quintiles will provide Basilea commercial services for the …

    Published on 8/18/2014
  • Biocad, Millhouse, Pharmstandard deal

    Biocad CJSC, Saint Petersburg, Russia Millhouse LLC, Moscow, Russia Pharmstandard OJSC (RTS:PHST;LSE:PHST), Dolgoprudny, Russia Business: Autoimmune, Cancer, Biosimilars Pharmstandard and Russian investment firm …

    Published on 8/18/2014
  • Celgene, Human Longevity deal

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Human Longevity Inc., San Diego, Calif. Business: Gene/Cell therapy, Musculoskeletal Celgenes Celgene Cellular Therapeutics subsidiary granted Human Longevity (HLI) rights to …

    Published on 8/18/2014
  • Celltrion, Mundipharma deal

    Celltrion Inc. (KOSDAQ:068270), Incheon, South Korea Mundipharma International Ltd., Cambridge, U.K. Business: Autoimmune Celltrions Celltrion Healthcare Hungary Kft subsidiary granted Mundipharma exclusive …

    Published on 8/18/2014
  • Enterprise Partners Venture Capital, Celladon deal

    Enterprise Partners Venture Capital, La Jolla, Calif. Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Business: Cardiovascular, Gene/Cell therapy Enterprise granted Celladon an exclusive, worldwide license to …

    Published on 8/18/2014
  • Enumeral Biomedical, Cerulean Group deal

    Enumeral Biomedical Holdings Inc. (OTCQB:ENUM), Cambridge, Mass. Cerulan Group Inc., Prague, Czech Republic Business: Antibodies Enumeral reverse-merged with shell company Cerulean Group and began trading on the OTCQB. …

    Published on 8/18/2014
  • Evotec, Shire deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic In May, Evotec partnered with Shire under a three-year deal to discover small molecule inhibitors …

    Published on 8/18/2014
  • Genomic Vision, Quest Diagnostics deal

    Genomic Vision S.A. (Euronext:GV), Paris, France Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic Genomic Vision said during 1H14 it met several milestones triggering a payment of EUR1.7 million ($2…

    Published on 8/18/2014
  • Gentris, Cancer Genetics deal

    Gentris Corp., Research Triangle Park, N.C. Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Supply/Service Cancer Genetics acquired Gentris, which provides next-generation sequencing and biomarker …

    Published on 8/18/2014
  • Gilead, Medicines Patent Pool deal

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Medicines Patent Pool, Geneva, Switzerland Business: Infectious Gilead expanded a 2011 deal with the Medicines Patent Pool to include non-exclusive rights for …

    Published on 8/18/2014
  • Grupo Farmaceutico Somar, Endo deal

    Grupo Farmaceutico Somar, Mexico City, Mexico Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Generics, Pharmaceuticals Endo completed its acquisition of Grupo Farmaceutico Somar for $268.8 …

    Published on 8/18/2014
  • H. Lee Moffitt Cancer Center, Lion Biotechnologies deal

    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla. Lion Biotechnologies Inc. (OTCQB:LBIO), Woodland Hills, Calif. Business: Cancer The center granted Lion exclusive, worldwide rights to IP covering …

    Published on 8/18/2014
  • Helsinn, Gen Pharmaceuticals deal

    Helsinn Healthcare S.A., Lugano, Switzerland Gen Pharmaceuticals Inc., Ankara, Turkey Business: Endocrine/Metabolic Helsinn granted Gen Pharmaceuticals exclusive rights to anamorelin (ONO-7643) in Turkey. Helsinn will …

    Published on 8/18/2014
  • Horizon Discovery, Otsuka Pharmaceutical deal

    Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: High throughput screening Horizon said its CombinatoRx division received a contract from Otsuka to perform in…

    Published on 8/18/2014
  • Icahn School of Medicine at Mount Sinai, Neurotrope BioScience deal

    Icahn School of Medicine at Mount Sinai, New York, N.Y. Neurotrope BioScience Inc., Plantation, Fla. Business: Neurology The medical school granted Neurotrope a worldwide, exclusive license to an information and data …

    Published on 8/18/2014
  • Infinity, FAAH Pharma deal

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. FAAH Pharma Inc., Montreal, Quebec Business: Neurology Infinity granted newco FAAH Pharma exclusive, worldwide rights to IPI-940, an oral fatty acid amide …

    Published on 8/18/2014
  • InoCard, uniQure deal

    InoCard GmbH, Heidelberg, Germany uniQure N.V. (NASDAQ:QURE), Amsterdam, the Netherlands Business: Cardiovascular, Gene/Cell therapy uniQure acquired InoCard for EUR1.5 million ($2 million) in cash and EUR1.5 million in…

    Published on 8/18/2014
  • Intrexon, Ziopharm deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. Ziopharm Inc., New Haven, Conn. Business: Cancer Ziopharm and Intrexon expanded a 2011 deal to develop and commercialize cell therapies against cancer using Intrexons …

    Published on 8/18/2014
  • Iroko, Calox de Costa Rica deal

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Calox de Costa Rica S.A., San Jose, Costa Rica Business: Neurology Irokos Iroko Pharmaceuticals Inc. affiliate granted Calox exclusive rights in Colombia, Costa Rica, …

    Published on 8/18/2014
  • J&J, Energesis Pharmaceuticals deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Energesis Pharmaceuticals, Cambridge, Mass. Business: Endocrine/Metabolic In June, Johnson & Johnsons Boston innovation center and the pharmas Janssen Pharmaceuticals …

    Published on 8/18/2014
  • Le Sun, Yabao Pharmaceutical Group deal

    Changzhou Le Sun Pharmaceuticals Ltd., Changzhou, China Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351), Beijing, China Business: Cancer Changzhou Le Sun granted Yabao exclusive rights in China to develop and …

    Published on 8/18/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993